UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 9.100

Sortiert nach

Ole e 1, Ole e 7, and Ole e 9: Identifying distinct clinical subsets of olive tree–allergic patients

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.629-631.e3

2016

Link zum Volltext

Verfügbarkeit prüfen

26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB120-AB120

2021

Link zum Volltext

Verfügbarkeit prüfen

Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

Circulation (New York, N.Y.), 2023-04, Vol.147 (16), p.1192-1203

2023

Link zum Volltext

Verfügbarkeit prüfen

Patterns of sensitization to inhalant allergens, Ole e 1 and Ole e 7 in children and adolescents born in the same area with different origin

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB129

2020

Link zum Volltext

Verfügbarkeit prüfen

26313 Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB97-AB97

2021

Link zum Volltext

Verfügbarkeit prüfen

S0653 Long-Term Treatment With Vedolizumab SC in Ulcerative Colitis: Interim Results From VISIBLE OLE

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S327-S327

2020

Link zum Volltext

Verfügbarkeit prüfen

Crystal structure of Pla l 1 reveals both structural similarity and allergenic divergence within the Ole e 1-like protein family

Journal of allergy and clinical immunology, 2017-07, Vol.140 (1), p.277-280

2017

Link zum Volltext

Verfügbarkeit prüfen

Lecanemab (BAN2401) Infusion Reactions and Immunogenicity: Results from Randomized Phase 2 Study and an Open‐Label Extension (OLE)

Alzheimer's & dementia, 2022-12, Vol.18 (S10), p.n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

34367 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB106-AB106

2022

Link zum Volltext

Verfügbarkeit prüfen

34358 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB180-AB180

2022

Link zum Volltext

Verfügbarkeit prüfen

Pollen Ole e 1 content variations in olive cultivars of different Portugal regions

Aerobiologia, 2021-06, Vol.37 (2), p.205-216

2021

Link zum Volltext

Verfügbarkeit prüfen

Needs for a thorough Joint Clinical Assessment of vaccines within the HTAR: perspectives of NITAGs: Ole Wichmann

European journal of public health, 2022-10, Vol.32 (Suppl 3)

Wichmann, O

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial

Journal of allergy and clinical immunology, 2022-02, Vol.149 (2), p.AB10-AB10

2022

Link zum Volltext

Verfügbarkeit prüfen

Lanadelumab efficacy and safety after switching from androgens: analysis of the phase 3 HELP and HELP OLE studies for hereditary angioedema

Journal of allergy and clinical immunology, 2022-02, Vol.149 (2), p.AB166-AB166

2022

Link zum Volltext

Verfügbarkeit prüfen

DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i110-i111

2023

Link zum Volltext

Verfügbarkeit prüfen

27419 Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB142-AB142

2021

Link zum Volltext

Verfügbarkeit prüfen

27424 Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB143-AB143

2021

Link zum Volltext

Verfügbarkeit prüfen

Attack-Free Status of Patients With Hereditary Angioedema (HAE) During Extended Treatment With Lanadelumab in the HELP OLE Study

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB104

2020

Link zum Volltext

Verfügbarkeit prüfen

Pru p 9 and Ole e 6-like, two new Peach tree pollen allergens, can elicit respiratory symptoms in children

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB72

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE)

Journal of allergy and clinical immunology, 2021-02, Vol.147 (2), p.AB24-AB24

2021

Link zum Volltext

Verfügbarkeit prüfen

Ole Petter Ottersen: on health and wealth

The Lancet (British edition), 2014-02, Vol.383 (9917), p.593-593

Holmes, David

2014

Link zum Volltext

Verfügbarkeit prüfen

Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy

Journal of allergy and clinical immunology, 2011-07, Vol.128 (1), p.178-184.e7

2011

Link zum Volltext

Verfügbarkeit prüfen

15108 Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB141-AB141

2020

Link zum Volltext

Verfügbarkeit prüfen

16292 Dupilumab treatment for up to 3 years demonstrates sustained efficacy in adult patients with moderate to severe atopic dermatitis: Results from LIBERTY AD Adult OLE

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB175-AB175

2020

Link zum Volltext

Verfügbarkeit prüfen

Increased Response to Higher Dose Lanadelumab in Hereditary Angioedema Patients: Exploratory Findings From the HELP and HELP OLE Studies

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB38-AB38

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 9.100

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Ovid Full Text

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(9.005)
Mit Volltextzugriff
(8.087)

Publikationsform

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(6.279)
Life Sciences & Biomedicine
(6.003)
Humans
(3.690)
Male
(2.542)
Female
(2.239)
Biological And Medical Sciences
(2.159)
Animals
(1.799)
Medical Sciences
(1.634)
Adult
(1.396)
Middle Aged
(1.311)
Neurosciences & Neurology
(1.100)
Neurosciences
(983)
Aged
(930)
Pharmacology & Pharmacy
(735)
Rats
(660)
Cardiovascular System & Cardiology
(656)
Fundamental And Applied Biological Sciences. Psychology
(637)
Biochemistry & Molecular Biology
(606)
Cardiac & Cardiovascular Systems
(520)
Pharmacology. Drug Treatments
(489)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Ole e 1, Ole e 7, and Ole e 9: Identifying distinct clinical subsets of olive tree–allergic patients

26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)

Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

Patterns of sensitization to inhalant allergens, Ole e 1 and Ole e 7 in children and adolescents born in the same area with different origin

26313 Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)

S0653 Long-Term Treatment With Vedolizumab SC in Ulcerative Colitis: Interim Results From VISIBLE OLE

Crystal structure of Pla l 1 reveals both structural similarity and allergenic divergence within the Ole e 1-like protein family

Lecanemab (BAN2401) Infusion Reactions and Immunogenicity: Results from Randomized Phase 2 Study and an Open‐Label Extension (OLE)

34367 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years

34358 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years

Pollen Ole e 1 content variations in olive cultivars of different Portugal regions

Needs for a thorough Joint Clinical Assessment of vaccines within the HTAR: perspectives of NITAGs: Ole Wichmann

Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial

Lanadelumab efficacy and safety after switching from androgens: analysis of the phase 3 HELP and HELP OLE studies for hereditary angioedema

DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients

27419 Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study

27424 Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study

Attack-Free Status of Patients With Hereditary Angioedema (HAE) During Extended Treatment With Lanadelumab in the HELP OLE Study

Pru p 9 and Ole e 6-like, two new Peach tree pollen allergens, can elicit respiratory symptoms in children

Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE)

Ole Petter Ottersen: on health and wealth

Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy

15108 Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)

16292 Dupilumab treatment for up to 3 years demonstrates sustained efficacy in adult patients with moderate to severe atopic dermatitis: Results from LIBERTY AD Adult OLE

Increased Response to Higher Dose Lanadelumab in Hereditary Angioedema Patients: Exploratory Findings From the HELP and HELP OLE Studies

Aktive Filter

Suchergebnisse filtern